---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-010514"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T06:20:09.623478+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Abeona Q1 net loss $12M; ZEVASKYN approved Apr 28, PRV sold for $155M

## Summary
- Net loss of $12.0M ($0.24/share) vs. $31.6M ($1.16/share) in Q1 2024; no revenue yet.
- FDA approved ZEVASKYN on Apr 28; first QTC (Lurie Children’s) activated, first patient expected Q3 2025.
- Entered asset purchase agreement to sell rare pediatric disease PRV for gross proceeds of $155M.
- Cash and investments $84.5M at Mar 31, 2025; PRV proceeds to extend runway into early 2026.
- ~30 patients registered in Abeona Assist; value-based agreements with payers covering ~100M lives.

## SEC filing metadata
- accession: 0001641172-25-010514
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000164117225010514/0001641172-25-010514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000164117225010514/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-010514
- JSON: https://secwatch.observer/filing/0001641172-25-010514.json
- Plain text: https://secwatch.observer/filing/0001641172-25-010514.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.